KRAS and pancreatic ductal adenocarcinoma: Further, the same group showed that combined inhibition of C-Raf and Egfr induced complete regression of pancreatic ductal adenocarcinomas in Kras/Trp53-driven GEM models and PDXs without apparent toxicity (77).